ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Rheostat launches to tackle neurodegenerative diseases

by Lisa M. Jarvis
December 2, 2018 | APPEARED IN VOLUME 96, ISSUE 48

 

Rheostat Therapeutics, a young biotech firm focused on treatments for neurodegeneration, cognition, and rare diseases, secured $23 million in its first formal round of funding. Rheostat is developing small molecules that can modulate the processes of mitophagy and autophagy, pathways used to rid cells of toxic components. MRLVentures Fund and AbbVie Ventures led the financing round, proceeds of which will be used to push Rheostat’s compounds into clinical studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment